Cited by 65Lipoproteins and Cardiovascular HealthCardiac Valve Diseases and TreatmentsAtherosclerosis and Cardiovascular Diseases

Increased Aortic Valve Calcification in Familial Hypercholesterolemia

Open access
ten Kate, Gert-Jan R., Bos, Sven, Dedic, Admir, Neefjes, Lisan A., Kurata, Akira, Langendonk, Janneke G., Liem, Anho, Moelker, Adriaan +5 more·2015·Journal of the American College of Cardiology

Abstract

Background Familial hypercholesterolemia is typically caused by LDL receptor (LDLR) mutations that result in elevated levels of LDL cholesterol (LDL-C). In homozygous FH, the prevalence of aortic valve calcification (AoVC) reaches 100% and is often symptomatic.Objectives The objective of this study was to investigate the prevalence, extent, and risk-modifiers of AoVC in heterozygous FH (he-FH) that are presently unknown.Methods Asymptomatic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent CT computed tomography calcium scoring. AoVC was defined as the presence of calcium at the aortic valve leaflets. The extent of AoVC was expressed in Agatston units, as the AoVC-score. We compared the prevalence and extent of AoVC between cases and controls. In addition, we investigated risk modifiers of AoVC, including the presence of LDLR mutations without residual function (LDLR-negative mutations), maximum untreated LDL-cholesterol (maxLDL), LDL-C, blood pressure, and coronary artery calcification (CAC).Results We included 145 asymptomatic patients with he-FH (93 men; mean age 52 ± 8 years) and 131 non-familial hypercholesterolemia controls. The prevalence (%) and AoVC-score (median, IQR) were higher in he-FH patients than in controls: 41%, 51 (9-117); and 21%, 21 (3-49) (p < 0.001 and p = 0.007). Age, untreated maxLDL, CAC, and diastolic blood pressure were independently associated with AoVC. LDLR-negative mutational he-FH was the strongest predictor of the AoVC-score (OR: 4.81; 95% CI: 2.22 to 10.40; p = <0.001).Conclusions Compared to controls, he-FH is associated with a high prevalence and a large extent of subclinical AoVC, especially in patients with LDLR-negative mutations, highlighting the critical role of LDL-C metabolism in AoVC etiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2015.09.087

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 42 · Cited by 65

Research works printed but not linked: 1

  1. Kawaguchi A, Miyatake K, Yutani C, et al. Characteristic cardiovascular manifestation in ho- mozygous and heterozygous familial hypercho- lesterolemia. Am Heart J 1999;137:410-8.

Authors
ten Kate, G.-J. R., Bos, S., Dedic, A., Neefjes, L. A., Kurata, A., Langendonk, J. G., Liem, A., Moelker, A., Krestin, G. P., de Feyter, P. J., Roeters van Lennep, J. E., Nieman, K., & Sijbrands, E. J.
Affiliations
  • Erasmus MC (NL)
  • Sint Franciscus Gasthuis (NL)
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2015-12
Volume
66
Issue
24
Pages
2687-2695
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2218954597
Cited by
65
References
42
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 2 · 2015: 1
FWCI
6.74
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Funders
  • Bayer HealthCare
  • Bracco Diagnostics
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
aortic valve calcification, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, LDL receptor mutations, LDL cholesterol, coronary artery calcification, diastolic blood pressure, aortic valve calcium score, risk factors
MeSH terms
Aortic Valve, Aortic Valve Stenosis, Calcinosis, Calcium, DNA, Echocardiography, Female, Humans, Hyperlipoproteinemia Type II, Lipoproteins, Male, Middle Aged, Mutation, Netherlands, Retrospective Studies, Risk Factors, Tomography, X-Ray Computed, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review